← Browse by Condition
Medical Condition
her2 low breast cancer
Total Trials
3
Recruiting Now
3
Trial Phases
Phase 3
NCT06210776
Recruiting
A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
Enrollment
800 pts
Location
China
Sponsor
Daiichi Sankyo
NCT07358182
Recruiting
Efficacy and Safety of Trastuzumab-rezetecan in HER2-Expressing Breast Cancer
Enrollment
300 pts
Location
China
Sponsor
Sun Yat-Sen Memorial Hospital ...
NCT06957886 Phase 3
Recruiting
A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer
Enrollment
566 pts
Location
China
Sponsor
Sichuan Baili Pharmaceutical C...